Affiliation:
1. Laboratory Affiliated to Pasteur Italia-Fondazione Cenci Bolognetti, Department of Biochemical Sciences, Sapienza University of Rome, 00185 Rome, Italy
2. UOC Genetica Medica, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy
Abstract
Antimicrobial resistance is a silent pandemic harming human health, and Pseudomonas aeruginosa is the most common bacterium responsible for chronic pulmonary and eye infections. Antimicrobial peptides (AMPs) represent promising alternatives to conventional antibiotics. In this review, the in vitro/in vivo activities of the frog skin-derived AMP Esc(1-21) are shown. Esc(1-21) rapidly kills both the planktonic and sessile forms of P. aeruginosa and stimulates migration of epithelial cells, likely favoring repair of damaged tissue. However, to undertake preclinical studies, some drawbacks of AMPs (cytotoxicity, poor biostability, and limited delivery to the target site) must be overcome. For this purpose, the stereochemistry of two amino acids of Esc(1-21) was changed to obtain the diastereomer Esc(1-21)-1c, which is more stable, less cytotoxic, and more efficient in treating P. aeruginosa-induced lung and cornea infections in mouse models. Incorporation of these peptides (Esc peptides) into nanoparticles or immobilization to a medical device (contact lens) was revealed to be an effective strategy to ameliorate and/or to prolong the peptides’ antimicrobial efficacy. Overall, these data make Esc peptides encouraging candidates for novel multifunctional drugs to treat lung pathology especially in patients with cystic fibrosis and eye dysfunctions, characterized by both tissue injury and bacterial infection.
Funder
EU funding within the NextGeneration EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases
Fondazione Italiana per la Ricerca sulla Fibrosi Cistica
Pasteur-Italia Fondazione Cenci Bolognetti-Anna Tramontano
Reference96 articles.
1. Antimicrobial Resistance Collaborators (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet, 399, 629–655.
2. New FDA approved antibacterial drugs: 2015–2017;Andrei;Discoveries,2018
3. European intensive care physicians’ experience of infections due to antibiotic-resistant bacteria;Lepape;Antimicrob. Resist. Infect. Control,2020
4. Tang, K.W.K., Millar, B.C., and Moore, J.E. (2023). Antimicrobial Resistance (AMR). Br. J. Biomed. Sci., 80.
5. Urban-Chmiel, R., Marek, A., Stepien-Pysniak, D., Wieczorek, K., Dec, M., Nowaczek, A., and Osek, J. (2022). Antibiotic Resistance in Bacteria-A Review. Antibiotics, 11.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献